Azenta Q1 FY2026: revenue up 1% to $149 million; non-GAAP EPS falls to $0.09
Azenta reported fiscal first-quarter 2026 results for the quarter ended December 31, 2025, with revenue of $149 million, up 1% year over year, but organic revenue declined 1%. Profitability weakened: non-GAAP diluted EPS was $0.09 versus $0.12 a year earlier, adjusted EBITDA fell to $13 million, and gross margin dropped to 42.9%. Management reiterated its fiscal 2026 guidance, which matters to shareholders because it signals the company still expects a stronger second half despite the margin pressure.
Key points
- Revenue was $149 million, up 1% year over year; organic revenue declined 1%.
- GAAP diluted EPS from continuing operations was ($0.11) versus ($0.16); total diluted EPS was ($0.34) including discontinued operations.
- Non-GAAP diluted EPS was $0.09 versus $0.12, and adjusted EBITDA margin was 8.5% versus 10.8%.
- Fiscal 2026 guidance reiterated: organic revenue growth of 3% to 5% and adjusted EBITDA margin expansion of approximately 300 basis points; the $63 million B Medical Systems sale is expected to close on or before March 31, 2026.
The filing
Written by AI on Nov 8, 2026, 1:54 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 04, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.